Solid Tumor Malignancies Recruiting Phase 2 Trials for Pemigatinib (DB15102)

Also known as: Solid Tumor Malignancy

IndicationStatusPhase
DBCOND0032723 (Solid Tumor Malignancies)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03822117Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)Treatment